Amgen Warns Of ‘Chaos’ In High Court Biosimilar Clash

Law360, New York (March 10, 2017, 10:06 PM EST) -- Amgen told the U.S. Supreme Court on Friday that biosimilar makers must divulge approval applications to innovator rivals and wait for product approval before giving the required notice of sales, warning that contrary views advocated by Sandoz would create “chaos.”

Amgen made the assertions in a 73-page brief, its opening salvo in a high-profile duel over competing interpretations of the Biologics Price Competition and Innovation Act. The case, set for argument next month, will determine how quickly lower-cost biosimilars hit pharmacy shelves and compete with pricey...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.